These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2082060)

  • 1. Effect of 3,3'-iminodipropionitrile on experimental intravitreal proliferation in albino rabbits.
    Akiyama K
    Jpn J Ophthalmol; 1990; 34(4):401-8. PubMed ID: 2082060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Efficacy and toxicity in the rabbit eye.
    Steinhorst UH; Chen EP; Hatchell DL; Samsa GP; Saloupis PT; Westendorf J; Machemer R
    Invest Ophthalmol Vis Sci; 1993 Apr; 34(5):1753-60. PubMed ID: 8473115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide.
    Tano Y; Chandler D; Machemer R
    Am J Ophthalmol; 1980 Dec; 90(6):810-6. PubMed ID: 7446668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of experimental proliferative vitreoretinopathy in rabbits].
    Kuriyama S; Ohuchi T; Okada M; Yamakawa R; Yoshimura N; Honda Y
    Nippon Ganka Gakkai Zasshi; 1990 Sep; 94(9):792-8. PubMed ID: 2248164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproliferative effect of mitomycin C on experimental proliferative vitreoretinopathy in rabbits.
    Yu HG; Chung H
    Korean J Ophthalmol; 1997 Dec; 11(2):98-105. PubMed ID: 9510652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N,N-dimethyladriamycin for treatment of experimental proliferative vitreoretinopathy: efficacy and toxicity on the rabbit retina.
    Steinhorst UH; Chen EP; Machemer R; Hatchell DL
    Exp Eye Res; 1993 Apr; 56(4):489-95. PubMed ID: 8500561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preretinal membrane formation in rabbit eyes after intravitreal transplantation of cultured astrocytes.
    Mishima N; Yamashita H; Ishii Y; Hori S
    Jpn J Ophthalmol; 1989; 33(4):501-18. PubMed ID: 2696800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil.
    Rubsamen PE; Davis PA; Hernandez E; O'Grady GE; Cousins SW
    Arch Ophthalmol; 1994 Mar; 112(3):407-13. PubMed ID: 8129669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of experimental intraocular proliferation with intravitreal 5-fluouracil.
    Binder S; Riss B; Skorpik C; Kulnig W
    Graefes Arch Clin Exp Ophthalmol; 1983; 221(3):126-9. PubMed ID: 6667861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further observations on the prevention of experimental proliferative vitreo-retinopathy by 5-fluorouracil.
    Ophir A
    Ophthalmic Res; 1991; 23(3):128-32. PubMed ID: 1945284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of intraocular proliferations with intravitreal steroids.
    Machemer R; Sugita G; Tano Y
    Trans Am Ophthalmol Soc; 1979; 77():171-80. PubMed ID: 545825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy.
    Stern WH; Lewis GP; Erickson PA; Guerin CJ; Anderson DH; Fisher SK; O'Donnell JJ
    Am J Ophthalmol; 1983 Jul; 96(1):33-42. PubMed ID: 6869478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy.
    Kirmani M; Santana M; Sorgente N; Wiedemann P; Ryan SJ
    Retina; 1983; 3(4):269-72. PubMed ID: 6201971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxol treatment of experimental proliferative vitreoretinopathy.
    Daniels SA; Coonley KG; Yoshizumi MO
    Graefes Arch Clin Exp Ophthalmol; 1990; 228(6):513-6. PubMed ID: 1979953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of 5-fluorouridine and 5-fluorouracil in an experimental model for the treatment of vitreoretinal scarring.
    Ward T; Hartzer M; Blumenkranz M; Lin LR
    Curr Eye Res; 1993 May; 12(5):397-401. PubMed ID: 8344064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).
    Diakonis VF; Tsourdou A; Tzatzarakis MN; Tsika C; Charisis S; Naoumidi I; Plainis S; Tsilimbaris MK
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):627-32. PubMed ID: 23556534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy.
    Hesse L; Nebeling B; Schroeder B; Heller G; Kroll P
    Exp Eye Res; 2000 Jan; 70(1):31-9. PubMed ID: 10644418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of intraocular proliferations with intravitreal corticosteroids.
    Tano Y; Sugita G; Abrams G; Machemer R
    Am J Ophthalmol; 1980 Jan; 89(1):131-6. PubMed ID: 6153251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy.
    Araiz JJ; Refojo MF; Arroyo MH; Leong FL; Albert DM; Tolentino FI
    Invest Ophthalmol Vis Sci; 1993 Mar; 34(3):522-30. PubMed ID: 8449673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraocular injection of silicone oil for experimental proliferative vitreoretinopathy.
    Fastenberg DM; Diddie KR; Delmage JM; Dorey K
    Am J Ophthalmol; 1983 May; 95(5):663-7. PubMed ID: 6846457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.